Oncology Venture has successfully executed capital increase with a value in excess of SEK 80m.


You May Also Like

miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial Evaluating MRG-106 in Subjects with Mycosis Fungoides

MRG-106 has been generally well-tolerated; Improvements in disease severity demonstrated and generally sustained through ...

Telix Pharmaceuticals Launches illumet™ Microsite (Kit for the Preparation of 68Ga-PSMA)

MELBOURNE, Australia and INDIANAPOLIS, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix ...